Literature DB >> 26098141

Single-arm Phase II cancer survival trial designs.

Jianrong Wu1.   

Abstract

The current practice for designing single-arm Phase II trials with time-to-event endpoints is limited to using either a maximum likelihood estimate test under the exponential model or a naive approach based on dichotomizing the event time at a landmark time point. A trial designed under the exponential model may not be reliable, and the naive approach is inefficient. The modified one-sample log-rank test statistic proposed in this article fills the void. In general, the proposed test can be used to design single-arm Phase II survival trials under any parametric survival distribution. Simulation results showed that it preserves type I error well and provides adequate power for Phase II cancer trial designs with time-to-event endpoints.

Entities:  

Keywords:  Clinical trial design; one-sample log-rank test; sample size; single-arm Phase II; survival analysis; time-to-event

Mesh:

Year:  2015        PMID: 26098141      PMCID: PMC5223772          DOI: 10.1080/10543406.2015.1052494

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  10 in total

1.  Designing phase II studies in cancer with time-to-event endpoints.

Authors:  Kouros Owzar; Sin-Ho Jung
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

2.  Sample size calculation for the one-sample log-rank test.

Authors:  Jianrong Wu
Journal:  Pharm Stat       Date:  2014-10-22       Impact factor: 1.894

3.  Sample size determination in clinical trials with time-dependent rates of losses and noncompliance.

Authors:  E Lakatos
Journal:  Control Clin Trials       Date:  1986-09

4.  Planning the size and duration of a clinical trial studying the time to some critical event.

Authors:  S L George; M M Desu
Journal:  J Chronic Dis       Date:  1974-02

5.  Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test.

Authors:  Minjung Kwak; Sin-Ho Jung
Journal:  Stat Med       Date:  2013-12-13       Impact factor: 2.373

6.  Sample-size formula for the proportional-hazards regression model.

Authors:  D A Schoenfeld
Journal:  Biometrics       Date:  1983-06       Impact factor: 2.571

7.  Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation.

Authors:  L V Rubinstein; M H Gail; T J Santner
Journal:  J Chronic Dis       Date:  1981

8.  Introduction to sample size determination and power analysis for clinical trials.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  1981-06

9.  Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.

Authors:  Xiaoqun Sun; Paul Peng; Dongsheng Tu
Journal:  Contemp Clin Trials       Date:  2010-10-01       Impact factor: 2.226

10.  Design of Phase II cancer trials evaluating survival probabilities.

Authors:  L Douglas Case; Timothy M Morgan
Journal:  BMC Med Res Methodol       Date:  2003-04-03       Impact factor: 4.615

  10 in total
  2 in total

1.  Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model.

Authors:  Jianrong Wu
Journal:  Stat Biopharm Res       Date:  2017-03-02       Impact factor: 1.452

2.  Reference curve sampling variability in one-sample log-rank tests.

Authors:  Moritz Fabian Danzer; Jannik Feld; Andreas Faldum; Rene Schmidt
Journal:  PLoS One       Date:  2022-07-21       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.